Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P960013/S135

Motorized Outer Tubing Cutter for UltiPace Leads

ABBOTT MEDICAL · Decision date Oct 9, 2026

MEDTECHLEDGER EXPLANATIONP960013/S135

What did the FDA decide?

FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-09 for P960013/S135, submitted by Abbott Medical. The supplement covers a process change attributed to a manufacturer, sterilizer, packager or supplier, and its stated scope is to implement automated cutting equipment for outer tubing used in UltiPace leads. The notice concerns the tubing-cutting step rather than a new lead design.

The underlying device category is drug eluting permanent right ventricular or right atrial pacemaker electrodes, classified under product code NVN in the Cardiovascular specialty. Because this is a PMA supplement, the record addresses the described manufacturing change only; it is not an approval of the whole system, and no clinical, efficacy or patient-selection conclusions follow from it. The source lists no supporting documents, so the technical content of the change and any conditions of the decision remain unknown.

FDA approval order statement

to implement automated cutting equipment for outer tubing used in UltiPace leads
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 9, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P960013/S135
Regulatory pathway
PMA supplement
Product code
NVN
Decision code
OK30
Decision date
Oct 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug eluting permanent right ventricular (RV) or right atrial (RA) pacemaker electrodes.

Product code
NVN
FDA device class
3

For the original device and its historical approval scope, see PMA P960013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P960013 · Original PMA

    TENDRIL DX MODEL 1388T & 1388K ENDOCARDIAL PACING LEADS

  2. P960013/S135 received

    Application receipt date recorded by FDA.

  3. P960013/S135 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P960013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P960013

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalJun 20, 1997FDA

Explore the linked device profile

Other records with product code NVN

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Cardiac Rhythm Disease ManagementPMA supplementOct 16, 2026FDA
Medtronic Cardiac Rhythm Disease ManagementPMA approvalAug 3, 2005FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
15900 Valley View Ct., Sylmar, CA, 91335

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records